New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 15, 2012
07:34 EDTHZNPHorizon Pharma's SkyeParma: USPTO issues notice of allowance for RAYOS tablets
Horizon Pharma announced that SkyePharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 2012/0177734 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to issue from this application will expire in 2024 for the U.S. patent. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Horizon CEO Timothy P. Walbert commented: "This patent allowance is a critical expansion of the patent estate for RAYOS. We are focused on protecting the commercial potential of RAYOS to 2024 and we will begin the RAYOS commercial launch this quarter."
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
07:31 EDTHZNPHorizon announces early termination of HSR waiting period for Vidara acquisition
Subscribe for More Information
April 14, 2014
11:09 EDTHZNPOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
April 11, 2014
10:35 EDTHZNPHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
Subscribe for More Information
April 10, 2014
07:35 EDTHZNPHorizon Pharma announces patent allowance from USPTO
Horizon Pharma announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2024. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the fifth U.S. patent to be listed in the Orange Book for RAYOS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use